Advertisement
ABOS vs PMN
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and PMN is a Hold.
ABOS's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for ABOS turned positive on October 21, 2026. Looking at past instances where ABOS's MACD turned positive, the stock continued to rise in 38 of 45 cases over the following month. The odds of a continued upward trend are 84%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where ABOS's RSI Indicator exited the oversold zone, 25 of 30 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
Following a +2.23% 3-day Advance, the price is estimated to grow further. Considering data from situations where ABOS advanced for three days, in 207 of 250 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
ABOS may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.
ABOS moved below its 50-day moving average on September 23, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for ABOS crossed bearishly below the 50-day moving average on September 25, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 19 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ABOS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 87%.
The Aroon Indicator for ABOS entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 73 (best 1 - 100 worst), indicating slightly worse than average price growth. ABOS’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.501) is normal, around the industry mean (3.035). P/E Ratio (-1.207) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ABOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Momentum Indicator for PMN turns negative, indicating new downward trend
PMN saw its Momentum Indicator move below the 0 level on October 22, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 105 similar instances where the indicator turned negative. In 100 of the 105 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
PMN moved below its 50-day moving average on September 21, 2026 date and that indicates a change from an upward trend to a downward trend.
The 50-day moving average for PMN moved below the 200-day moving average on October 13, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PMN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for PMN entered a downward trend on October 23, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where PMN's RSI Indicator exited the oversold zone, 29 of 32 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 56 of 64 cases where PMN's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 88%.
The Moving Average Convergence Divergence (MACD) for PMN just turned positive on October 21, 2026. Looking at past instances where PMN's MACD turned positive, the stock continued to rise in 41 of 50 cases over the following month. The odds of a continued upward trend are 82%.
Following a +5.37% 3-day Advance, the price is estimated to grow further. Considering data from situations where PMN advanced for three days, in 158 of 189 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
PMN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 85 (best 1 - 100 worst), indicating slightly worse than average price growth. PMN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 91 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.514) is normal, around the industry mean (3.035). P/E Ratio (-0.661) is within average values for comparable stocks, (-1.360). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.535) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. PMN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
PMN | ||
|---|---|---|
OUTLOOK RATING 1..100 | 50 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 91 Overvalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 85 | |
P/E GROWTH RATING 1..100 | 10 | |
SEASONALITY SCORE 1..100 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| ABOS | PMN | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 83% | 3 days ago 90% |
| Stochastic ODDS (%) | 3 days ago 85% | 3 days ago 88% |
| Momentum ODDS (%) | N/A | 3 days ago 90% |
| MACD ODDS (%) | 3 days ago 84% | 3 days ago 82% |
| TrendWeek ODDS (%) | 3 days ago 84% | 3 days ago 79% |
| TrendMonth ODDS (%) | 3 days ago 83% | 3 days ago 90% |
| Advances ODDS (%) | 4 days ago 83% | 17 days ago 84% |
| Declines ODDS (%) | 11 days ago 87% | 3 days ago 90% |
| BollingerBands ODDS (%) | 3 days ago 79% | 3 days ago 90% |
| Aroon ODDS (%) | 3 days ago 89% | 3 days ago 89% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ABOS’s FA Score shows that 1 FA rating(s) are green while PMN’s FA Score has 1 green FA rating(s).
- ABOS’s FA Score: 1 green, 4 red.
- PMN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ABOS’s TA Score shows that 4 TA indicator(s) are bullish while PMN’s TA Score has 5 bullish TA indicator(s).
- ABOS’s TA Score: 4 bullish, 5 bearish.
- PMN’s TA Score: 5 bullish, 5 bearish.
Price Growth
ABOS (@Biotechnology) experienced а +17.16% price change this week, while PMN (@Biotechnology) price change was +2.33% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +1.24%. For the same industry, the average monthly price growth was -16.30%, and the average quarterly price growth was -16.78%.
Reported Earning Dates
ABOS is expected to report earnings on Oct 26, 2026.
PMN is expected to report earnings on Nov 11, 2026.
Industries' Descriptions
@Biotechnology (+1.24% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| ZSB | 20.59 | N/A | N/A |
| USCF Sustainable Battery Metals Strategy Fund (ZSB) | |||
| KTF | 8.15 | -0.01 | -0.12% |
| DWS Municipal Income Trust | |||
| CCSB | 19.56 | -0.03 | -0.15% |
| Carbon Collective Short Duration Green Bond ETF (CCSB) | |||
| FMAY | 57.26 | -0.18 | -0.31% |
| FT Vest U.S. Equity Buffer Fund - May (FMAY) | |||
| GMOV | 33.05 | -0.27 | -0.81% |
| GMO US Value ETF | |||
ABOS and
Correlation & Price change
A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with CCXI. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then CCXI could also see price increases.
| Ticker / NAME | Correlation To ABOS | 1D Price Change % | ||
|---|---|---|---|---|
| ABOS | 100% | -3.88% | ||
| CCXI - ABOS | 48% Loosely correlated | -0.05% | ||
| EDIT - ABOS | 46% Loosely correlated | -3.61% | ||
| SANA - ABOS | 42% Loosely correlated | -1.69% | ||
| RCKT - ABOS | 41% Loosely correlated | -0.87% | ||
| NKTX - ABOS | 41% Loosely correlated | +2.87% | ||
More | ||||
PMN and
Correlation & Price change
A.I.dvisor indicates that over the last year, PMN has been loosely correlated with CNSP. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if PMN jumps, then CNSP could also see price increases.
| Ticker / NAME | Correlation To PMN | 1D Price Change % | ||
|---|---|---|---|---|
| PMN | 100% | -3.58% | ||
| CNSP - PMN | 51% Loosely correlated | -1.03% | ||
| SYRE - PMN | 44% Loosely correlated | -2.17% | ||
| BBIO - PMN | 42% Loosely correlated | +0.65% | ||
| ABOS - PMN | 33% Poorly correlated | -3.88% | ||
| CTNM - PMN | 33% Poorly correlated | -1.01% | ||
More | ||||